All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

/images/Cortellis_Flagship_Logo_TM_RGB_Color.png
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Artificial intelligence
    • Coronavirus
    • Diagnosing and tracking COVID-19
    • Drugs to Watch 2020
    • The next pandemic
    • Premium reports
      • BioWorld Financings Reports
      • Disease Forecast Reports

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, March 7, 2021
Home » Blogs » BioWorld Perspectives » After Three Decades, Finally, Biotech’s Little Dividend

BioWorld Perspectives
BioWorld Perspectives RSS FeedRSS

BioWorld

After Three Decades, Finally, Biotech’s Little Dividend

April 26, 2011
By Lynn Yoffee
No Comments

Remember when the promise of biotech was a mere twinkle of innovation in some researcher’s eyes? An investor’s long-term bet? Depending on how you label a biotech company, Amgen Inc.’s first-ever payment of a quarterly dividend last week marks an important step in the growth of the world’s largest biotech and the industry as a whole. How many other pure-play biotechs have reported the same news? None.

It wasn’t a surprise. The big biotech has about $15 billion in cash and has been criticized by some for not returning money to its shareholders. Still, I was surprised at the lack of hoopla over such a milestone. Is our innovative sector so mainstream now that its first dividend wasn’t worth a round of applause? Instead, it was just another bullet point in analysts’ key takeaway reports:

Robert W. Baird & Co. analyst Christopher Raymond told BioWorld Insight that health care companies that initiated a dividend in the past decade saw their share price shoot up an average of 12.7 percent over the 180 days bracketing the announcement of a first dividend. That’s good news.

Oppenheimer's Bret Holley pointed out that even though the initial yield will be small, Amgen expects the payout to rise over time, and “Although we believe dividend/buyback growth should attract new investors to AMGN, we expect this will take time,” he wrote. Positive predictions for the long term.

But, ho hum . . . just another day in the now-mature biotech sector.

(None are so old as those who have outlived enthusiasm. ? Henry David Thoreau)

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld

    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

  • Today's news in brief

    BioWorld
    BioWorld briefs for March 5.
  • Gloved hand places sample tubes in PCR system

    COVID-19 test makers are adapting for variants

    BioWorld MedTech
    As COVID-19 variants have emerged, so have questions about the effectiveness of tests for infection. While the risk of mutations significantly limiting their...
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech's briefs for March 5.
  • Coronavirus vaccine/therapeutics illustration

    Tonix looks to the past for the future of COVID-19 vaccines and testing

    BioWorld MedTech
    Tonix Pharmaceuticals Holding Corp. is looking to lessons from tuberculosis and smallpox to guide its future in infectious diseases. The company is developing an...
cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • About
    • Archives
    • Today's news
    • Search BioWorld Science
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
A Clarivate Analytic solution. Link to Clarivate website.
Follow Us

Copyright ©2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing